What question did this study set out to answer?

To evaluate the impact and effectiveness of the FAST4TMA initiative for rapid ADAMTS13 testing in TMA patients.

December 8, 2025Blood

FAST4TMA: A national rapid ADAMTS13 testing initiative for TMA patients — 2025 update

View Full Paper

Ask AI

Bookmark

Authors

National initiative enhances cost-effectiveness of ADAMTS13 testing in thrombotic microangiopathy, suggesting improved patient management outcomes.

To evaluate the impact and effectiveness of the FAST4TMA initiative for rapid ADAMTS13 testing in TMA patients.
Implemented a national program providing free same-day ADAMTS13 testing and mobile phlebotomy services.
Coordinated testing via a centralized high-throughput reference lab for eligible inpatient and outpatient TMA cases.
Conducted provider surveys to assess clinical utility and gather feedback on implementation.
Received 420 ADAMTS13 samples; 8.8% showed severe deficiency, and over half displayed more than 30% activity.
Economic modeling indicated $10,788 in per-patient hospital savings, potentially totaling $4.34 million for 402 patients.
100% of providers reported improvement in patient care, and 88% noted enhanced adherence to testing protocols.

Martin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

National initiative enhances cost-effectiveness of ADAMTS13 testing in thrombotic microangiopathy, suggesting improved patient management outcomes.